Seres Therapeutics, Inc. (MCRB) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Seres Therapeutics is a clinical-stage biopharmaceutical company focused on developing live biotherapeutics (LBPs) to treat infections and inflammatory/immune diseases. Following the sale of its VOWST business to Nestlé Health Science in September 2024, the company is now a smaller, less diversified entity focused on its pipeline, primarily SER-155 (for bloodstream infections in allo-HSCT patients and immune checkpoint-related enterocolitis) and SER-603 (for inflammatory bowel disease). The company has implemented significant cost-reduction measures, including a 30% workforce reduction in February 2026.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $358 | $0 |
| Net Loss | $(19,913) | $32,682 (Income) |
| Net Loss Per Share (Basic/Diluted) | $(2.08) | $3.76 / $3.75 |
| Cash and Cash Equivalents | $29,834 | $45,766 |
| Total Assets | $117,618 | $138,193 |
| Accumulated Deficit | $(992,316) | $(972,403) |
| Operating Cash Flow | $(16,360) | $26,910 |
Revenue Composition: Q1 2026 revenue consisted entirely of $358,000 in grant revenue from CARB-X. There was no product sales revenue.
Expense Breakdown: Total operating expenses were $21.3 million, comprising $13.2 million in R&D and $8.1 million in G&A. Manufacturing services expenses were $0, as the Transition Services Agreement (TSA) with Nestlé concluded in December 2025.
Material Changes vs. Prior Period
- Reversal of Net Income: The company reported a net loss of $19.9 million in Q1 2026, compared to net income of $32.7 million in Q1 2025. The prior year's income was driven by a $52.2 million gain on the sale of the VOWST business and $6.3 million in TSA reimbursement income, neither of which occurred in Q1 2026.
- Expense Reductions: G&A expenses decreased by $3.8 million year-over-year due to lower headcount, reduced professional fees, and the cessation of TSA-related reimbursable costs. R&D expenses increased by $1.4 million, primarily due to the reclassification of facility costs previously reimbursed under the TSA and startup activities for the SER-155 Phase 2 study.
- Cash Burn: Cash and cash equivalents decreased by approximately $16 million during the quarter, reflecting the net loss and operating cash outflows.
Guidance, Outlook, and Risks
Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for 12 months from the date of issuance. The company anticipates requiring additional funding following the third quarter of 2026. If capital cannot be raised, the company may need to implement further cost reductions, delay programs, or consider bankruptcy.
Strategic Outlook:
- SER-155: The Phase 2 study in allo-HSCT has been paused pending funding, despite FDA protocol submission in January 2026. An investigator-sponsored trial (IST) for immune checkpoint-related enterocolitis (irEC) is nearing completion, with results expected soon.
- SER-603: Preclinical development for IBD is ongoing, with IND-enabling activities in progress.
- SER-428: Development of an oral liquid formulation for ICU patients is supported by a CARB-X grant.
Key Risks:
- Liquidity: Limited cash runway necessitates immediate capital raising or strategic partnerships.
- Lease Obligations: Significant excess leased space remains following workforce reductions, creating a fixed cost burden.
- Regulatory & Clinical: Risks associated with clinical trial outcomes, regulatory approvals for novel live biotherapeutics, and potential FDA disruptions.
- Intellectual Property: Ongoing litigation risks regarding patent infringement (e.g., Vedanta Biosciences complaint).
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the anticipated funding requirement post-Q3 2026 and the status of any active fundraising efforts or partnership discussions.
- Lease Commitments: Review the total future minimum lease payments ($113.4 million undiscounted) and the company's strategy for subleasing excess space to mitigate fixed costs.
- SER-155 Phase 2 Status: Confirm the conditions required to resume the paused Phase 2 study and the timeline for the irEC IST data readout.
- Going Concern Mitigation: Assess the probability of securing the necessary financing given the current market environment and the company's reduced asset base.
- Legal Contingencies: Monitor the status of the patent infringement lawsuit filed by Vedanta Biosciences and The University of Tokyo.